Dogwood Therapeutics, Inc. - Common Stock, $0.0001 par value (DWTX)
CUSIP: 92829J203
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Shares outstanding
- 29,716,833
- Total 13F shares
- 43,200
- Share change
- -38,769
- Total reported value
- $207,544
- Price per share
- $4.77
- Number of holders
- 10
- Value change
- -$197,053
- Number of buys
- 3
- Number of sells
- 7
Quarterly Holders Quick Answers
What is CUSIP 92829J203?
CUSIP 92829J203 identifies DWTX - Dogwood Therapeutics, Inc. - Common Stock, $0.0001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92829J203:
Top shareholders of DWTX - Dogwood Therapeutics, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| William Pridgen |
3/4/5
|
Director |
—
mixed-class rows
|
764,196
mixed-class rows
|
$992,479 | — | 26 Feb 2024 | |
| Orca Capital AG |
13D/G
|
— |
3.7%
|
69,821
|
$390,299 | -$256,967 | 14 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.1%
|
29,818
|
$149,389 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
14,409
|
$72,195 | — | 31 Mar 2025 | |
| FNY Investment Advisers, LLC |
13F
|
Company |
0.04%
|
12,500
|
$62,000 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.04%
|
11,782
|
$59,028 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.04%
|
11,228
|
$56,000 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,050
|
$5,260 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
600
|
$3,006 | — | 31 Mar 2025 | |
| CK Life Sciences Intl (Holdings) Inc |
3/4/5
|
Director, Other*, 10%+ Owner |
—
class O/S missing
|
284
|
$1,993 | — | 12 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0%
|
225
|
$1,127 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
188
|
$942 | — | 31 Mar 2025 | |
| Activest Wealth Management |
13F
|
Company |
0%
|
120
|
$601 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
30
|
$150 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
10
|
$50 | — | 31 Mar 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
9
|
$45 | — | 31 Mar 2025 | |
| Richard Alan Burch |
3/4/5
|
Director |
—
class O/S missing
|
2,917
|
— | — | 26 Feb 2024 | |
| Abel de la Rosa |
3/4/5
|
Director |
—
class O/S missing
|
2,362
|
— | — | 27 Jun 2025 | |
| David R. Keefer |
3/4/5
|
Director |
—
class O/S missing
|
2,362
|
— | — | 27 Jun 2025 | |
| John C. Thomas |
3/4/5
|
Director |
—
class O/S missing
|
2,362
|
— | — | 27 Jun 2025 | |
| Richard James Whitley |
3/4/5
|
Director |
—
class O/S missing
|
2,362
|
— | — | 27 Jun 2025 |
Institutional Holders of Dogwood Therapeutics, Inc. - Common Stock, $0.0001 par value (DWTX) as of Q2 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.